Browsing Tag
MatrixCare
2 posts
ResMed’s FY27 guidance reset tests investor confidence in sleep-apnea device growth
ResMed’s FY27 guidance reset pressured RMD despite strong cash flow. Read how Astral, GLP-1 drugs, MatrixCare and buybacks shape the medtech story.
ResMed (ASX: RMD) drops 8% as Astral recall clouds FY27 outlook
ResMed fell 8% as FY27 sales guidance missed expectations. Astral recall costs and slower growth now test the ASX: RMD valuation.